Biological Warfare

Better Controls in DOD's Research Could Prevent Unneeded Expenditures Gao ID: NSIAD-91-68 December 27, 1990

Pursuant to a congressional request, GAO assessed the medical component of the Department of Defense's (DOD) Biological Defense Research Program, operated by the Army's Medical Research and Development Command.

GAO found that: (1) the Army's lack of adequate internal controls resulted in its allocation of at least $47 million for 49 research projects that did not address validated biological warfare threat agents; (2) there was no requirement for the Army to search other federal research databases to prevent duplication of research efforts; (3) nearly one-third of the medical products that the Army developed for U.S. military forces did not address validated biological warfare threat agents; (4) between 1965 and 1990, the Army invested about $45 million in developing and producing 16 medical products, and spent over $19 million on 5 medical products that did not address validated threats; and (5) the Army continues to develop medical products that do not address validated threats.

Recommendations

Our recommendations from this work are listed below with a Contact for more information. Status will change from "In process" to "Open," "Closed - implemented," or "Closed - not implemented" based on our follow up work.

Director: Team: Phone:


The Justia Government Accountability Office site republishes public reports retrieved from the U.S. GAO These reports should not be considered official, and do not necessarily reflect the views of Justia.